Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
11.75B
Market cap11.75B
Price-Earnings ratio
-3.65
Price-Earnings ratio-3.65
Dividend yield
Dividend yield
Average volume
9.56M
Average volume9.56M
High today
$30.44
High today$30.44
Low today
$29.21
Low today$29.21
Open price
$29.50
Open price$29.50
Volume
12.31M
Volume12.31M
52 Week high
$48.92
52 Week high$48.92
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

The current Moderna(MRNA) stock price is $29.31, with a market capitalization of 11.75B. The stock trades at a price-to-earnings (P/E) ratio of -3.65.

During the trading session on 2025-12-13, Moderna(MRNA) shares reached a daily high of $30.44 and a low of $29.21. At a current price of $29.31, the stock is +0.3% higher than the low and still -3.7% under the high.

Trading activity shows a volume of 12.31M, compared to an average daily volume of 9.56M.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

MRNA News

TipRanks 19h
Moderna price target lowered to $28 from $30 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps an Equal Weight rating on the shares. The firm expects many of the po...

TipRanks 1d
Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating

Moderna (MRNA) has received a new Hold rating, initiated by Jefferies analyst, Andrew Tsai. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-b...

Seeking Alpha 1d
Moderna on track to extend gains for the seventh straight trading day

Moderna (NASDAQ:MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29.65 on Thursday. MRNA has added 20....

Moderna on track to extend gains for the seventh straight trading day

Analyst ratings

62%

of 26 ratings
Buy
19.2%
Hold
61.5%
Sell
19.2%

More MRNA News

Bloomberg 2d
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge

The US risks falling behind in biotechnology as the government cuts funding and skepticism over vaccines grows, according to Moderna Inc.’s co-founder and Chair...

Moderna Founder Warns US Doubts on Science Threaten Biotech Edge
TipRanks 4d
Moderna’s Growth Prospects: Balancing Revenue Potential and Legal Challenges

Moderna, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Hold rating on...

TipRanks 5d
Mixed options sentiment in Moderna with shareslittle changed

Mixed options sentiment in Moderna (MRNA), with sharesflat near $27.70. Options volume relatively light with 44k contracts traded and calls leading puts for a p...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.